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Summary Twenty-one nephrectomized patients with metastatic renal cell cancer were treated with recombinant interleukin 2 (rlL-2) and
interferon alpha (rlFNa). rlL-2 was administered s.c. at a dose of 1 x 106 U im-2 every 12 h on days 1 and 2, followed by 0.5 x 106 IU twice daily
on days 3-5; rlFNa-2 was given i.m. as 1.8 x 106 IU m-2 on days 3 and 5 of each week for 4 consecutive weeks. The cycle was regularly
repeated at 4-month intervals and continued ad libitum in patients showing some response and in patients with progressing disease. Of 20
patients evaluable for treatment response, one (5%) had a complete response and three (15%) showed partial response. Three patients
(15%) achieved stable disease and 13 (65%) were evaluated as having progressive disease. The estimated actuarial 44-month survival rate
was 44%. Toxicity was limited to WHO grades 1 and 2 only.
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Interleukin 2 (rIL-2)-based immunotherapy is the only reliable
option for metastatic renal cell cancer (mRCC). Initial rIL-2
schedules were developed using chemotherapy guidelines in
which the maximum tolerable dose was given by intravenous
bolus orcontinuous infusion over afew days. Despite encouraging
results (response rates of 14-30%, with complete and lasting
remissions in approximately 3-5% of patients), the use of high-
dose rIL-2 results in severe toxicity and some drug-related fatali-
ties (Rosenberg et al, 1987; West et al, 1987). Lower doses of
rIL-2 given both alone and in combination with rIFNa were asso-
ciated with less acute toxicity, although with similar response rate
andimmunological activity as high-dose schedules (Caligiuri etal,
1990; Schneekloth et al, 1993; Vlasveld et al, 1993). Again, only
these patients stable or responding after one or two cycles
continued to be treated. Thus, the optimal dose and schedule of
low-dose immunotherapy has yet to be determined.
In the present phase II study, a treatment cycle with very low
dose rIL-2 and rIFNa ofmRCC patients was chronically repeated
in all patients, irrespective oftheir response. The rationale for this
approach was based on the following assumptions: (1) low-dose
rIL-2 displays anti-tumour effects and immunomodulant activity
selectively addressed to the expansion ofnatural killer cells and of
antigen-stimulated T lymhocytes (Caligiuri, 1993; Vlasveld et al,
1993), whereas high-dose rIL-2 can reduce immune responsive-
ness both depressing delayed-type hypersensitivity and inducing
programmed T-cell death (Wiebke et al, 1988; Lenardo, 1991); (2)
the expansion of lymphocyte subsets induced by rIL-2 lasts for 1
or 2 months from the end of the treatment (Sondel et al, 1988;
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Schneekloth et al, 1993); (3) reiterated low-dose immunotherapy
given on a regular basis could boost immune responsiveness,
eventually overcoming tumour-induced anergy (Caligiuri, 1993).
The present study was aimed at evaluating whether an immune
response that is chronically stimulated is able to induce a persis-
tent control ofmRCC with acceptable toxicity.
PATIENTS AND METHODS
Twenty-one consecutive patients with progressing mRCC were
enrolled in an open, non-randomized phase II study. Before entry,
all patients were evaluated by physical examination, computerized
tomographic scan of the brain, chest and abdomen, and radio-
nuclide bone scan. Patients' characteristics are shown in Table 1.
The enrolled patients were grouped in three groups according to a
prognostic index, taking into account weight loss > 10% within the
previous 6 months, ECOG performance status and erythrocyte
sedimentation rate (Palmer et al, 1992; Fossa et al, 1994). Ten
(48%) patients were classified as goodriskandfive (24%) as inter-
mediate risk. The remaining six (28%) patients were classified as
poor risk. All patients underwent nephrectomy before systemic
therapy. Other inclusion criteria were age below 70 years and
adequate renal, hepatic and thyroid functions. Patients were
excluded if they had evidence of central nervous metastases,
serious active infections or had previously received any antineo-
plastic treatment. The protocol was reviewed and accepted by the
local ethics committee. Signed informed consent was obtained
from each patient before entry into the study. In almost all patients
(90%), the treatment was started within 6 months from the diag-
nosis ofmetastasis.
In an outpatient setting, rIL-2 was self-administered s.c. for 5
days per week and rIFNa was given i.m. twice weekly for 4
consecutive weeks corresponding to one therapeutic cycle. The
cycle was regularly repeated at 4-month intervals both in
responding and in progressing patients. In the patients achieving
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Table 1 Patients' characteristics
Number of patients
Median age (range) (years)
Female
Male
Performance status (ECOG)a
0
1
2
Time from diagnosis to first metastasis
< 6 months
.6 months
21
64 (28-70)
5 (24%)
16 (76%)
12 (57%)
4 (19%)
5 (24%)
16 (76%)
5 (24%)
Time from diagnosis to treatment
< 6 months 15 (72%)
.6 months 6 (28%)
Disease sites
Lymph node 11 (52%)
Lung 10 (48%)
Local relapse 5 (24%)
Bone 4 (19%)
Kidney 3 (14%)
Others 9 (43%)
Number of metastatic sites
One organ site 10 (48%)
Two organ sites 5 (24%)
> Three organ sites 6 (28%)
Sedimentation rate (mm)b
< 50 11 (53%)
50-99 7 (33%)
> 100 3 (14%)
Weight lossc
< 10% 15 (71%)
. 10% 6 (29%)
aEastern Cooperative Oncology Group. bWestergren method (mm/first hour).
cDunng the last 6 months.
complete remission, the interval period between cycles was subse-
quently shifted to 6 months.
rIL-2 (Proleukin; EuroCetus, Amsterdam, the Netherlands) was
administered at a dose of 1 million IU m-2 every 12 h on days 1
and 2, followed by 0.5 x 106 IU m-2 twice daily on days 3-5 of
each week. Concomitantly, rIFNa-2b (Intron-A; Schering, USA)
orrIFNa-2a (Roferon-A; Roche, Basle, Switzerland) was given as
1.8 million IU m-2 on days 3 and 5. No therapy was administered
on days 6 and 7.
A pilot study performed in another set of five mRCC patients
showed that the above schedule was able to determine significant
increases of lymphocyte and eosinophil counts as well as of a
number of lymphocyte subsets (CD3+, CD4+, CD8+, CD56+,
CD25+ and DR+) (data not shown). In addition, not only the first
but also subsequent cycles determined significant immunological
changes.
All patients underwent physical examination and routine labora-
tory evaluation before and after each cycle. Performance status
(PS) was defined according to ECOG. We used a SMAC contin-
uous-flow analyser to determine the activities ofaminotransferases
andgamma-glutamyltransferase and toquantify the serum concen-
trations of total bilirubin and creatinine. ELISA commercial kits
were used to measure T3, T4, TSH and anti-thyroid antibodies.
Approximately every 6 months, all known sites of the disease
were evaluated for response by appropriate radiological examina-
tion. Full restage was performed every 12 months in all patients.
Responses, according to WHO recommendations (Miller et al,
1981), were evaluated by the investigators and reviewed by an
independent radiologist. Toxicity was also graded according to
WHO-recommended criteria.
Response and survival rates were calculated from the time of
the first dose ofrIL-2. Patient survival was estimated by using the
Kaplan-Meier method.
RESULTS
Immunotherapy was administered for a total of 102 treatment
cycles. The median number of immunotherapy cycles was three
(range 1-13). One patient was judged to be non-evaluable for
response because of inadequate post-study assessment of
metastatic measurements. Of 20 patients evaluable for treatment
response, one (5%) obtained a complete response and three (15%)
showed a partial response, the overall response rate being, there-
fore, 20% (95% confidence interval 6-44%). Three (15%)
patients showed a stable disease and 13 (65%) a progressive
course of the disease. At entry, the prognostic index was good in
the seven patients showing some response or stable disease,
whereas it was intermediate orpoor in 10 out ofthe 13 progressing
patients.
One woman with a single lung (18 x 12 mm) metastasis, devel-
oped 10 months after nephrectomy, achieved a complete response
after the first treatment cycle. She continued the planned therapy
and the duration ofcomplete remission was 55+ months. The three
partial responders had two known sites of metastasis, concerning
the controlateral kidney andretroperitoneal lymph nodes, lung and
local relapse, lung and mediastinal lymph nodes. In the first
patient, the diameters of the renal metastasis decreased from
40 x 40 to 34 x 30 mm, and two lymph nodes (both with
maximum diameter of20 mm) completely disappeared; the partial
response persisted for 37+ months. The second one showed
pulmonary metastasis that was not significantly changed (35 x 35
to 32 x 25 mm) by therapy but local bulk decreasing more than
50% (57 x50 mm to 30 x 30 mm). The patient died after 7 months
from ischaemic cerebral infarction. In the remaining patient, a
lung metastasis reduced its diameters from 20 x 20 to 5 x 5 mm,
but mediastinal nodes (about 18 x 18 mm) were unaffected by
therapy. The partial response persisted for as long as 18 months.
Thereafter, a progressive disease was seen again. However, he
remained in treatment and is still living after 48+ months. The
partial response was seen after the third treatment cycle in one
case, but the other two objective responses occurredjust after the
first cycle.
One out of the three patients with stable disease was submitted
to surgical excision of a single lung metastasis after two treatment
cycles. She remained without evidence ofdisease for 41+ months.
The remaining two patients had stable disease throughout the
follow-up (12+ months forboth).
Nine out of the thirteen progressive patients bearing two or
more known sites of metastasis died from cancer-related causes
after a median survival time of 7 months (range 5-13 months).
Another patient showing local relapse (24 x 20 mm) and supra-
clavicular lymph node (45 x 41 mm) metastases, both confirmed
by fine-needle aspiration biopsy, shifted fromprogressive to stable
disease after five treatment cycles. However, he developed
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Figure 1 Survival time of 21 patients with metastatic RCC treated with
repeated cycles at very low doses ofrlL-2 andrlFNa-2
Table 2 Systemic toxicity of treatment with very low doses of rlL-2 and
rlFNa-2
Percent of 102 treatment cycles
Severity gradinga Grade 0 Grade 1 Grade 2
Malaise/fatigue 37 49 14
Chills 54 39 7
Fever 20 50 30
Anorexia 64 25 11
Weight loss 81 14 5
Nausea/vomiting 94 2 4
Diarrhoea 95 3 2
Pyrosis 61 12 27
Arthralgias/myalgias 40 56 4
Cardiac arrhythmias 98 0 2
Aspartate/alanine aminotransferase 77 20 3
Gamma-glutamyltransferase 79 20 1
*Toxicity grades based on World Health Organization criteria.
progression in the same metastatic sites 18 months later. The
remaining three patients showing single, although progressing,
lesions were subjected to excision of metastases 7, 12 and 16
months from the beginning of the therapy. One of these patients
remained without evidence of disease for 24+ months after
removal of an ethmoidal metastasis; another relapsed early after
surgery ofaretroperitoneal mass and died 27 months later. Finally,
the third patient who underwent resection of single controlateral
kidney metastasis relapsed in the same site 15 months later.
The patient judged to be non-evaluable for response had a
residual viable tumour in ipsilateral psoas at the time of nephrec-
tomy but remained free ofprogression for 45+ months.
The overall survival curve for 21 patients with mRCC is shown
in Figure 1. The estimated actuarial 44-month survival rate was
44%. The PS was equal to 0 in all ten patients who were alive.
Table 2 shows the incidence and severity oftoxicity experienced
by the patients during 102 treatment cycles. Toxicity was
moderate, never requiring either inpatient treatment or discontinu-
ation of therapy. Fever, chills, fatigue and malaise occurred in all
patients and, in most cases, were completely reversible to the end
ofeach treatment cycle. Anorexia and mild gastrointestinal symp-
toms were observed in seventeen patients; pyrosis needed antacid
suspension treatment in ten cases. Transient rises in serum amino-
transferases and/or gamma-glutamyltransferase were apparent in
nine patients. However, biochemical evidence of hepatic toxicity
reversed to normal values in all patients aftercompleting the cycle.
Cardiac side-effects included atrial fibrillation in one patient and
ventricular extrasystoles in another. Administration of rIL-2
resulted in transient inflammation and induration at the injection
sites persisting for up to 2 weeks after the cycle.
Thyroiddysfunction was observed in 6of21 patients (29%). Five
of them showed biochemical hyperthyroidism at the end of every
cycle, spontaneously resolving before the subsequent treatment.
One patient developed hyperthyroidism followed by symptomatic
Table 3 Current treatments of advanced renal cell cancer with low doses of rlL-2 and rlFNa given subcutaneously and intramuscolarly
respectively
Authors Dose per schedule
rlL-2 rlFNa
Atzpodien et al (1990) 9 x 106 IU m-2 every 12 h 5 x 106 IU m-2 day-' for 3 days weekly
for 2 days followed by for 6 weeks
1.8 x 106 IU m-2 every 12 h
for 5 days weekly for 6 weeks
Atzpodien et al (1991) 14.4-18 x 106 IU m-2 day-' for 3-6 x 106 IU m2 day-' for 2-3 days
2 days followed by weekly for 6 weeks
3.6-4.8 x 106 IU m-2 day-' for
5 days weekly for 6 weeks
Lissoni et al (1993) 9 x 106 JU m-2 every 12 h 5 x 106 IU m-2 day-' for 3 days weekly
for 2 days followed by for 6 weeks
3x 106 U m-2 every 12h
for 5 days weekly for 6 weeks
Vuoristo et al (1994) 2.4 x 106 IU m-2 every 12 h 3 x 106 IU m-2 day-' for 2 days weekly
for 5 days weekly for 6 weeks for 2 weeks
6 x 106 IU m-2 day-'
for 3 days weekly for 4 weeks
Buzio et al (present study) 1 x 106 IU m-2 every 12 h for 1.8 x 106 IU m-2 day-' for
2 days followed by 2 days weekly for 4 weeks
0.5 x 106 IU m-2 every 12 h
for 3 days weekly for 4 weeks
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hypothyroidism requiring treatment for 18+ months. Abnormal
increases in antithyroglobulin and antimicrosomal antibodies were
seen in two cases.
DISCUSSION
In studies using low doses of s.c. rIL-2 and i.m. IFNa to treat
mRCC, rIL-2 was administered at doses ranging from 144 x 106 to
216 x 106 LU m-2 per cycle, while rIFNa was given at doses
ranging from 36 x 106 to 108 x 106 IU m-2 per cycle, and the treat-
ment cycle was repeated a few times but only in stable or respon-
sive patients (Table 3).
In the present study, the drastic reduction in both rIL-2 and
rIFN-a dosages (respectively about five- to eightfold and three- to
eightfold lower than in other low-dose treatment cycles) provided
an overall response rate of20%, i.e. exactly the same reported in a
recent large trial concerning 149 advanced RCC patients treated
with a high-dose bolus rIL-2 (Rosenberg et al, 1994).
In the present study, the immunotherapy was at fixed intervals
(every 4 months) repeated ad libitum not only in responding but
also in progressing patients. Because of short follow-up or early
death for cancer-related causes, ten out ofthe twenty-one patients
received only one to three cycles, whereas a median of seven
cycles (range 4-13 cycles) were received by the remaining eleven
patients. Interestingly, two patients showed a late effect of the
therapy, the first patient achieving a partial response after the third
cycle and the second one shifting from progressive to stable
disease after five treatment cycles (about 2 years from the begin-
ning oftherapy).
In agreement withprevious reports (Palmeretal, 1992; Fossaetal,
1994), the present study shows that clinical response and prolonged
survival time are mostly seen in the patients showing good prog-
nostic index. This clearly suggests that immunotherapy is able to
control only a subset ofmRCC patients -about40% in this trial.
There is growing consensus about the fact that objective anti-
tumour response may not be the most important end point to be
used to evaluate the efficacy ofimmunotherapy. A low growth of
the tumour, resulting from a sustained immunological attack, may
also benefit the patient. Thus, survival andperformance status may
be more appropriate parameters to compare treatment outcomes. A
recent study (Rosenberg et al, 1994) reported an actuarial 36-
month survival rate of 34% in metastatic RCC patients treated
with high-dose bolus rIL-2. In the present study, the estimated
actuarial 36-month survival rate of mRCC patients was 51%, and
the ten patients still living at the last observation showed a very
good PS (equal to 0). These results summarize the impact of
immunotherapy on the natural history ofmRCC, as about 10% of
mRCC patients have an expected 3-year survival rate (Bottiger,
1970). However, survival data from non-randomized phase II
studies have little value because ofselection bias, and randomized
studies are necessary to compare survival data from different
immunotherapeutic schedules.
In our patients, toxicity ofrIL-2 was reduced to a level that was
quite manageable on an ambulatory oncology ward. Toxicity was
not related to the number of cycles, therefore we could repeat the
treatment many times (up to 13 cycles todate) in all mRCC patients.
In summary, this study shows that repetitive cycles with very
low doses ofrIL-2 and rIFNa-2 bring about an objective response
rate of 20% and a 44-month survival rate of 44%. Treatment-
related toxicity is limited to WHO grades ofseverity 1 and 2 only.
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